SS&C Announces Common Stock Dividend of $0.20 Per Share
WINDSOR, Conn., Aug. 18, 2022 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced its Board of Directors has approved a quarterly dividend payout of $0.20 per share, consistent with its quarterly dividend policy. The dividend is payable on September 15, 2022, to stockholders of record as of the close of business on September 1, 2022.
About SS&C Technologies
SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. Some 20,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology.
Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.
Allegion plc , a leading global security products and solutions provider, today reported financial results for its first quarter (ended March 31, 2024).
"Allegion's Q1 performance sets a solid foundation for the year," said John H. Stone, Allegion...
Breach Secure Now, the channel leader in providing cybersecurity and productivity training and solutions, is pleased to announce the appointment of Dan Cucchi as its new Vice President of Sales. In this role, Cucchi will oversee the company's sales...
PureTech Health plc ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024. The following information represents select highlights from...
A new report from the Bitrue throws down the gauntlet to Big Tech, highlighting how decentralized GPU (Graphics Processing Unit) rental markets could democratize access to computational power and disrupt the current AI resource landscape.
The report...
Soft2Bet already operates the market-leading Betinia website in Denmark and is set to once again revolutionise the market with CampoBet, a mobile-first sportsbook, and casino that will provide an unparalleled gaming experience to Danish players....
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...
